Objectlve:To evaluate the toxicities of palliative chemotherapy combination XELOX in the treatment of advanced stage gastric cancer. Patients and methods: 52 inoperable advanced stage gastric cancer patients treated by palliative chemotherapy combination XELOX from 01/2011 to 06/2013 in K hospital. The prospective descriptive study. Results: The most often seen toxicity was anemia, 69,2 percent, mild to moderate grades. Neutropenia accounted for 67,3 percent, in which grade 3 accounted for 11,5 percent, none was neutropenic fever. Nephrotocixity 11,5 percent and all was mild grade. Hepatotoxicity was grad 1-2 transaminase elevation, 41,2 percent. The non hematoxicities predominantly were mild to moderate grade vomiting, oral mucositis and diarrhea. Hand-foot syndrome 42,2 percent in which 1,9 percent severe grade leading to dose reduce. There was correlation between neutropenia and the age older than 60 or full dose treatment. Conclusion: The combination XELOX was quite safe with seldomly seen severe grade toxicity. So that it could be used for elderly advanced gastric cancer patients.
- Đăng nhập để gửi ý kiến